ReviewInternational journal of molecular sciences2024
Cardiovascular Effects of Herbal Products and Their Interaction with Antihypertensive Drugs-Comprehensive Review.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Coumarins in hypertension management: from vascular signaling pathways to clinical perspectives.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Harnessing Medicinal Plants Through Advanced Drug Delivery: A New Era in Type 2 Diabetes Management.Pharmaceutics · 2026Review
- Cardioprotective Effects ofLife (Basel, Switzerland) · 2026Review
- Potential Adverse Effects of Ashwagandha: A Critical Review of Preclinical and Clinical Evidence.Phytotherapy research : PTR · 2026Review
- Natural Products as Nutritional Supplements in Human Disease Prevention and Management: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
- Optimizing immersion time and frequency in a twin-bottle temporary immersion system for mass production of Zingiber officinale Roscoe.Scientific reports · 2026Article
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Immunomodulatory effect of allium sativum in type 2 diabetes mellitus.World journal of experimental medicine · 2025Review
- Inorganic Element Identification and In Vitro Preliminary Evaluation of Three Types of Standardized Black Chokeberry Extracts Against Human Pulmonary Artery Endothelial Cells (HPAECs).Plants (Basel, Switzerland) · 2025Article
- Cardiometabolic Effects ofNutrients · 2025Observational
- Green Tea: Current Knowledge and Issues.Foods (Basel, Switzerland) · 2025Review
- Natural metabolites used in traditional Chinese medicine for cardiovascular diseases: pharmacological mechanisms, evidence, and future directions.Frontiers in pharmacology · 2025Review
- Review
- Article
- Ginsenoside RbChinese herbal medicines · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a highly prevalent population-level disease that represents an important risk factor for several cardiovascular complications and occupies a leading position in mortality statistics. Antihypertensive therapy includes a wide variety of drugs. Additionally, the potential antihypertensive and cardioprotective effects of several phytotherapy products have been evaluated, as these could also be a valuable therapeutic option for the prevention, improvement or treatment of hypertension and its complications. The present review includes an evaluation of the cardioprotective and antihypertensive effects of garlic, Aloe vera, green tea, Ginkgo biloba, berberine, ginseng, Nigella sativa, Apium graveolens, thyme, cinnamon and ginger, and their possible interactions with antihypertensive drugs. A literature search was undertaken via the PubMed, Google Scholar, Embase and Cochrane databases. Research articles, systematic reviews and meta-analyses published between 2010 and 2023, in the English, Hungarian, and Romanian languages were selected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.